SCHEMBL12440967

SCHEMBL12440967

Cc1cc(C)c(OC(C)C)c(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MCL1 Q07820 1/20 0.40
KDM4E B2RXH2 5/20 0.39
LMNA P02545 5/20 0.39
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
FFAR4 Q5NUL3 1/20 0.36
POLB P06746 2/20 0.34
ALOX12 P18054 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
USP2 O75604 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ATM Q13315 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12517837 0.84 FFAR4 (0.41) MAPTALDH1A1FFAR4GAA
SCHEMBL12330469 0.80 LMNA (0.33) MEN1KMT2ALMNAALOX12NPSR1
SCHEMBL13429928 0.80 LMNA (0.33) MEN1KMT2AMCL1LMNAALOX12
SCHEMBL16334835 0.80 LMNA (0.33) MAPTMEN1KMT2AMCL1LMNA
SCHEMBL3316427 0.77 LMNA (0.34) MEN1KMT2AMCL1KDM4ELMNA
SCHEMBL12514195 0.77 MEN1 (0.37) MAPTL3MBTL1MEN1KMT2AMCL1
SCHEMBL13429688 0.76 LMNA (0.31) MAPTL3MBTL1LMNAALOX12NPSR1
SCHEMBL5085895 0.76 MAPT (0.51) MAPTL3MBTL1MEN1KMT2AMCL1
SCHEMBL2544650 0.76 LMNA (0.36) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL20958220 0.75 ALDH1A1 (0.43) MAPTKDM4ELMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9318706-B2 Laminated structure, method for producing same, and electronic element comprising same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-04-19 US disclosed
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US disclosed
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-21 US disclosed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME EPCAM, ITGA1, ITGB1 MAPT 456/4885L3MBTL1 4308/4885MEN1 1758/4885
US-20100234324-A1 Quinazolinamide derivatives HSP90AB1, HSP90AA1, HSP90AB2P MAPT 1744/4885L3MBTL1 1578/4885MEN1 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.